Cardiovascular therapy developer Milestone Pharmaceuticals will use proceeds from the Novo-led round to advance its lead candidate to a phase 3 clinical trial.
Milestone Pharmaceuticals, a Canada-based developer of therapies aimed at cardiovascular conditions, raised $55m yesterday in a series C round led by pharmaceutical firm Novo.
BDC Capital, the investment arm of state-owned Business Development Bank of Canada, and Fonds de solidarité FTQ, the capital development organisation for Quebec, also took part along with Forbion Capital Partners, Domain Associates, Pappas Capital, Go Capital and funds managed by Tekla Capital Management.
Founded in 2005, Milestone Pharmaceuticals is working on treatments for cardiovascular conditions.…